7.05
+0.09
+(1.29%)
At close: 4:00:00 PM EDT
6.96
-0.09
(-1.28%)
After hours: 4:53:04 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
23,612
23,612
--
10,161
28,650
Cost of Revenue
7,417
7,417
2,173
222
2,059
Gross Profit
16,195
16,195
25,288
9,939
26,591
Operating Expense
103,198
103,198
74,892
34,841
18,862
Operating Income
-87,003
-87,003
--
-24,902
7,729
Net Non Operating Interest Income Expense
-5,176
-5,176
--
1,178
-115
Other Income Expense
2,039
2,039
--
-3,081
-16,135
Pretax Income
-90,140
-90,140
--
-26,805
-8,521
Tax Provision
15,371
15,371
--
-33
34
Net Income Common Stockholders
-105,511
-105,511
--
-26,772
-62,897
Diluted NI Available to Com Stockholders
-105,511
-105,511
--
-26,772
-62,897
Basic EPS
-2.13
-2.28
-1.30
-1.20
-2.11
Diluted EPS
-2.13
-2.28
-1.30
-1.20
-2.11
Basic Average Shares
42,562.29
46,251.24
35,452.46
34,488.80
29,766.35
Diluted Average Shares
42,562.29
46,251.24
35,452.46
34,488.80
29,766.35
Total Operating Income as Reported
-87,003
-87,003
--
-42,565
7,729
Total Expenses
110,615
110,615
--
35,063
20,921
Net Income from Continuing & Discontinued Operation
-105,511
-105,511
--
-26,772
-8,555
Normalized Income
-107,121.81
-107,121.81
--
-23,694.70
3,223.55
Interest Income
2,175
2,175
--
1,513
261
Interest Expense
7,351
7,351
--
335
376
Net Interest Income
-5,176
-5,176
--
1,178
-115
EBIT
-82,789
-82,789
--
-26,470
-8,145
EBITDA
-76,400
-76,400
--
-25,526
-7,888
Reconciled Cost of Revenue
7,263
7,263
1,939
222
2,059
Reconciled Depreciation
6,389
6,389
--
944
257
Net Income from Continuing Operation Net Minority Interest
-105,511
-105,511
--
-26,772
-8,555
Total Unusual Items Excluding Goodwill
2,039
2,039
--
-3,081
-16,135
Total Unusual Items
2,039
2,039
--
-3,081
-16,135
Normalized EBITDA
-78,439
-78,439
--
-22,445
8,247
Tax Rate for Calcs
0
0
--
0
0
Tax Effect of Unusual Items
428.19
428.19
--
-3.70
-4,356.45
12/31/2021 - 4/16/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SNDX Syndax Pharmaceuticals, Inc.
11.05
-2.47%
STOK Stoke Therapeutics, Inc.
7.56
-2.45%
XFOR X4 Pharmaceuticals, Inc.
0.1953
-6.11%
DAWN Day One Biopharmaceuticals, Inc.
6.76
-5.98%
TYRA Tyra Biosciences, Inc.
8.61
-0.58%
MGTX MeiraGTx Holdings plc
5.32
-2.39%
PBYI Puma Biotechnology, Inc.
2.8800
-2.70%
TVTX Travere Therapeutics, Inc.
14.57
-2.28%
FBIO Fortress Biotech, Inc.
1.5000
-1.32%
LENZ LENZ Therapeutics, Inc.
23.06
-3.47%